Lisa Lewin, Author at Precision Value & Health

Precision Medicine Group Appoints John Hubbard, PhD, as Board of Directors Chair

Lisa Lewin2023-03-14T13:03:20+00:00Events, News|

BETHESDA, MD, March 14, 2023 – Precision Medicine Group (PMG), a leading next-generation provider of drug development and commercialization services, today announced the appointment of John Hubbard, PhD, as Chairman of its Board of Directors.

“We are thrilled to welcome John to our Board. He is a highly regarded leader in the pharmaceutical industry with extensive experience in clinical development and operations, strategic planning and business development,” said Mark Clein, Chief Executive Officer of Precision Medicine Group. “His impressive qualifications make him uniquely qualified to appreciate the breadth of services offered across our organization and to provide valuable insight as we continue to expand our global footprint and integrated capabilities.”

(more…)

Stern IR Launches an ESG Advisory Practice

Lisa Lewin2023-03-03T16:59:18+00:00Events, News|

Stern IR, part of Precision Value & Health, enhances market leadership position by integrating IR expertise, deep biotech knowledge, and ESG solutions to bring substantive value to clients. ESG Expert Molly Podolefsky, PhD, to lead complementary new ESG capability

NEW YORK, March 2, 2023 — Stern IR, Inc., a Precision Value & Health company, today announced the launch of its new environmental, social, and governance (ESG) advisory practice. The addition of the ESG practice will deliver a suite of solutions, including materiality assessments, ESG strategy and roadmap development, reporting, and communications packages that are well integrated with Stern’s core investor relations (IR) competencies. These complementary ESG solutions are designed to meet the evolving IR needs of biotechnology and healthcare companies, which increasingly involve and are influenced by ESG considerations and factors with ESG rapidly becoming a core component of best-in-class IR.

(more…)

Weathering the Storm: Cell and Gene’s Economic Downturn

Lisa Lewin2023-02-21T20:37:32+00:00Thought Leadership|

After record-setting milestones in fundraising over the past two years, the advanced therapy investment landscape is experiencing a natural correction. Precision’s Anshul Mangal and Dr. James M. Wilson outline in this The Medicine Maker article how industry leaders can ensure the advancement of innovative treatments for patients with #rarediseases by consolidating investments and prioritizing partnerships with patient advocacy organizations.

READ THE ARTICLE HERE!

Webinar: Let’s Talk: Moving CGTx Clinical Development Forward in 2023

Lisa Lewin2023-02-21T15:57:15+00:00Events, Thought Leadership|

Sponsored by Precision ADVANCE, this Endpoints webinar will convene leading advanced therapy experts to discuss the future of CGTx clinical development. This discussion will be moderated by Teresa Pokladowski: Regional VP, Clinical Business Solutions (Precision for Medicine), and include insights from Kinnari Patel: President & COO (Rocket Pharmaceuticals), Suma Krishnan: Founder & President (Kystal Biotech), Dawn Buchanan: VP Clinical Operations (AffyImmune), and Ramona Repaczki-Jones: Executive Director, Commercial Treatment Center Operations, Cell Therapy (lovance Biotherapeutics, Inc).

(more…)

White Paper: State of the Union for Advanced Medicines

Lisa Lewin2023-02-21T16:33:26+00:00Thought Leadership|

The cell and gene therapy (CGTx) sector has flourished over the last 2 to 5 years due to continued investor confidence. However, the recent downturn in public markets has undermined that confidence.

This white paper is based on a panel discussion, sponsored by Precision ADVANCE, featuring insights from diverse industry perspectives on the current state of the CGTx sector; the investment landscape; scientific and technical advances; progress in drug development, manufacturing, regulatory, pricing, and reimbursement; and expected key trends in 2023 and beyond. Hosted by Endpoints News, the panel included insights from the following industry leaders:

Anshul Mangal: President (Project Farma & Precision ADVANCE)
Dave Greenwald: Vice President of Business Development (Deerfield Management)
Rajul Jain: Managing Director (Vida Ventures)
Joseph LaBarge: Chief Executive Officer (Apertura Gene Therapy)
Adrian Woolfson: Executive Chairman, President and Co-Founder (Replay Bio)
Phil Cyr: Executive Vice President (Precision Value & Health)

(more…)

The Tripledemic as a Precursor to Stakeholder Alignment under the Quintuple Aim

Lisa Lewin2023-02-21T15:27:57+00:00Thought Leadership|

October 2022 heralded another crisis for hospitals and physicians: the tripledemic. It likely won’t be the last season for a potential infectious disease calamity, so every healthcare stakeholder must play a role in mitigating the damage. However, issues such as staffing, vaccine fatigue, misinformation, and operational challenges may inhibit successful interventions. Precision’s Maureen Hennessey and Cynthia Miller argue for the need to create a wholistic pandemic strategy that align’s with the Quintuple Aim and supports the five aims: care-team well being, better patient care, healthier people, affordability, and health equity.

READ THE ARTICLE HERE!

Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma

Lisa Lewin2023-02-21T16:52:19+00:00Thought Leadership|

New study demonstrates the feasibility of systematically integrating long-term survival estimates obtained from a formal expert elicitation study with empirical clinical trial data through a case study.

Learn more about recent work of PRECISIONheor’s Shannon Cope (co-primary author), Kevin Towle and Ali Mojebi and their co-authors HERE!

Social Media’s Complex Climb

Lisa Lewin2023-01-28T14:00:51+00:00Thought Leadership|

As new channels enter the healthcare conversation mix, engagement strategies are changing. Social media, previously an incremental investment for pharma, is now foundational. Precision’s Christian Rodgers, SVP, Social Media, explains why in “Zoom star replaced the podium star” in Pharmaceutical Executive.

READ THE ARTICLE HERE!

QuartzBio, a Part of Precision for Medicine, Acquires SolveBio and Expands Software-as-a-Service (SaaS) Data Management Solutions for Clinical Research & Development (R&D)

Lisa Lewin2023-01-28T20:37:00+00:00Events, News|

QuartzBio, a Part of Precision for Medicine, Acquires SolveBio and Expands Software-as-a-Service (SaaS) Data Management Solutions for Clinical Research & Development (R&D)

QuartzBio’s suite of end-to-end SaaS solutions provides pharmaceutical and biotech clients with a fully connected data ecosystem linking sample, biomarker, and clinical data to improve collaboration, planning and R&D productivity

Frederick, MD – January 24, 2023 Precision for Medicine, the first global, precision medicine clinical research services organization, today announced the strategic acquisition of SolveBio by QuartzBio.

(more…)

PRECISIONscientia’s DOL Map named one of the most Innovative Products of 2022 by PM360 Magazine

Lisa Lewin2023-05-28T22:33:06+00:00News|

The continued growth of social and digital communications has ushered in new channels for the exchange of ideas and opinions. And now, these channels have given rise to new voices of influence—Digital Opinion Leaders (DOLs). To help pharma marketers identify and gain insights on DOLs in specific therapeutic areas, PRECISIONscientia has developed a powerful, web-based proprietary platform, DOL Map. The platform delivers an intuitive experience that summarizes each DOL’s impact, reach, and relevance to clients’ disease focus. DOL Map focuses on key components to find the right DOLs for any commercial brand or product in development: relevance, reach and audience engagement, impact on audience, and authenticity.

PRECISIONscientia’s DOL Map was named one of the most Innovative Products of 2022 by PM360 Magazine. Read the article HERE!

About Lisa Lewin